Evidence map›Paper›PMID 35563629›Full record

ArticleInternational journal of molecular sciences2022

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.

Jonas Feldheim, Almuth F Kessler, Julia J Feldheim, Ellina Schulz, David Wend, Lazaros Lazaridis, Christoph Kleinschnitz, Martin Glas, Ralf-Ingo Ernestus, Sebastian Brandner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Jonas FeldheimSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Almuth F KesslerSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Julia J FeldheimSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Ellina SchulzSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
David WendSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Lazaros LazaridisDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, D-45131 Essen, Germany.
Christoph KleinschnitzDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, D-45131 Essen, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, D-45131 Essen, Germany.
Ralf-Ingo ErnestusSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Sebastian BrandnerDivision of Neuropathology, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College Hospitals NHS Foundation Trust, London WC1N3BG, UK.
Camelia M MonoranuDepartment of Neuropathology, Institute of Pathology, University of Würzburg, D-97080 Würzburg, Germany.
Mario LöhrSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.
Carsten HagemannSection Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, D-97080 Würzburg, Germany.ORCID 0000-0001-9759-8149
University of Würzburg · DEEssen University Hospital · DEUniversity College Hospital · GB

Funding

Cancer research UK Centre Accelerator Award A21922German National Academic Foundation noneGraduate School of Life Sciences Würzburg noneJunior clinician scientist fellowship University of Essen noneOpen Access Publication Fund of the University of Würzburg noneUK Department of Health's NIHR Biomedical Research Centre 's funding scheme to University College hospitals NHS foundation trust none
6 · The paper itself

Abstract

Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O

Indexed as

AstrocytomaBrain NeoplasmsGlioblastomaAntineoplastic Agents, AlkylatingDNA MethylationDNA Modification MethylasesDNA Repair EnzymesHumansIsocitrate DehydrogenaseNeoplasm Recurrence, LocalTemozolomideWorld Health OrganizationAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesIsocitrate DehydrogenaseTemozolomideastrocytomacancer stem cellsglioblastomaIDHMGMTtemozolomidetherapy

Identifiers

PMID35563629
PMCPMC9100657
OpenAlexW4229332288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.